Cite

HARVARD Citation

    Flygt, H. et al. (2021). Long‐term tolerability and efficacy after initial PegIFN‐α addition to dasatinib in CML‐CP: Five‐year follow‐up of the NordCML007 study. European journal of haematology. pp. 617-623. [Online]. 
  
Back to record